SK902004A3 - Kryštály obsahujúce soľ N-[2-(dietylamino)etyl]-5-[(5-fluór-2- oxo-3H-indol-3-ylidén)metyl]-2,4,dimetyl-1H-pyrrol-3-karboxamidu s kyselinou jablčnou, spôsob ich výroby a kompozície na ich báze - Google Patents

Kryštály obsahujúce soľ N-[2-(dietylamino)etyl]-5-[(5-fluór-2- oxo-3H-indol-3-ylidén)metyl]-2,4,dimetyl-1H-pyrrol-3-karboxamidu s kyselinou jablčnou, spôsob ich výroby a kompozície na ich báze Download PDF

Info

Publication number
SK902004A3
SK902004A3 SK90-2004A SK902004A SK902004A3 SK 902004 A3 SK902004 A3 SK 902004A3 SK 902004 A SK902004 A SK 902004A SK 902004 A3 SK902004 A3 SK 902004A3
Authority
SK
Slovakia
Prior art keywords
crystal
malic acid
pyrrole
diethylamino
fluoro
Prior art date
Application number
SK90-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Michael Hawley
Thomas J. Fleck
Stephen P. Prescott
Mark T. Maloney
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK902004(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of SK902004A3 publication Critical patent/SK902004A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
SK90-2004A 2001-08-15 2002-08-13 Kryštály obsahujúce soľ N-[2-(dietylamino)etyl]-5-[(5-fluór-2- oxo-3H-indol-3-ylidén)metyl]-2,4,dimetyl-1H-pyrrol-3-karboxamidu s kyselinou jablčnou, spôsob ich výroby a kompozície na ich báze SK902004A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15
PCT/US2002/025649 WO2003016305A1 (en) 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Publications (1)

Publication Number Publication Date
SK902004A3 true SK902004A3 (sk) 2005-03-04

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
SK90-2004A SK902004A3 (sk) 2001-08-15 2002-08-13 Kryštály obsahujúce soľ N-[2-(dietylamino)etyl]-5-[(5-fluór-2- oxo-3H-indol-3-ylidén)metyl]-2,4,dimetyl-1H-pyrrol-3-karboxamidu s kyselinou jablčnou, spôsob ich výroby a kompozície na ich báze

Country Status (43)

Country Link
US (2) US20030069298A1 (hu)
EP (3) EP2332934B1 (hu)
JP (1) JP4159988B2 (hu)
KR (1) KR100639281B1 (hu)
CN (2) CN100364991C (hu)
AP (1) AP1660A (hu)
AR (1) AR036261A1 (hu)
AU (1) AU2002324684B2 (hu)
BG (1) BG108553A (hu)
BR (1) BR0211612A (hu)
CA (1) CA2455050C (hu)
CO (1) CO5550431A2 (hu)
CU (1) CU23713B7 (hu)
CY (1) CY1121552T1 (hu)
CZ (1) CZ2004196A3 (hu)
DK (2) DK3168218T3 (hu)
EA (1) EA006445B9 (hu)
EC (1) ECSP044975A (hu)
ES (3) ES2623094T3 (hu)
GE (1) GEP20063777B (hu)
HK (2) HK1066542A1 (hu)
HR (1) HRP20040112B1 (hu)
HU (1) HU229206B1 (hu)
IL (1) IL160097A0 (hu)
IS (1) IS7147A (hu)
MA (1) MA27058A1 (hu)
ME (1) ME00414B (hu)
MX (1) MXPA04001452A (hu)
MY (1) MY139383A (hu)
NO (1) NO326508B1 (hu)
NZ (1) NZ531232A (hu)
OA (1) OA12650A (hu)
PL (1) PL216524B1 (hu)
PT (2) PT1419151E (hu)
RS (1) RS53251B (hu)
SI (2) SI3168218T1 (hu)
SK (1) SK902004A3 (hu)
TN (1) TNSN04028A1 (hu)
TR (1) TR201900509T4 (hu)
TW (1) TWI269796B (hu)
UA (1) UA76483C2 (hu)
WO (1) WO2003016305A1 (hu)
ZA (1) ZA200400706B (hu)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364991C (zh) 2001-08-15 2008-01-30 法玛西雅厄普约翰美国公司 2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
CA2540639C (en) * 2003-10-02 2010-08-31 Pharmacia & Upjohn Company Llc Salts and polymorphs of a pyrrole-substituted indolinone compound
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
JP4922163B2 (ja) * 2004-07-22 2012-04-25 イーライ リリー アンド カンパニー （ｓ）−６−（４−（２−（（３−（９ｈ−カルバゾール−４−イルオキシ）−２−ヒドロキシプロピル）アミノ）−２−メチルプロピル）フェノキシ）−３−ピリジンカルボキサミドヘミコハク酸塩の結晶質の不定比水和物
BRPI0609957A2 (pt) * 2005-05-12 2010-05-11 Pfizer uso de malato de sunitinib na preparação de um medicamento para o tratamento de cáncer
SI1928858T1 (sl) * 2005-09-19 2009-10-31 Pfizer Prod Inc Trde solne oblike s pirolom substituiranega 2-indolinona
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
KR20100069705A (ko) * 2007-11-21 2010-06-24 테바 파마슈티컬 인더스트리즈 리미티드 수니티닙 헤미-ｌ-말레이트, 이의 다형 및 제조 방법, 라세미 수니티닙 말레이트의 다형, 수니티닙 염기 및 말산을 함유하는 조성물 및 이의 제조 방법
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CN101939314B (zh) * 2007-12-12 2014-04-02 麦迪凯姆股份公司 3-吡咯取代的2-吲哚酮的多晶型物
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009104021A2 (en) * 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
KR20100119582A (ko) * 2008-03-31 2010-11-09 테바 파마슈티컬 인더스트리즈 리미티드 수니티닙 및 이의 염을 제조하는 방법
CA2720943A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
US8829039B2 (en) 2008-05-23 2014-09-09 Shanghai Institute Of Pharmaceutical Industry Dihydroindolinone derivatives
AR072117A1 (es) * 2008-06-13 2010-08-04 Medichem Sa Procedimiento para preparar una sal de malato 3-pirrol sustituido 2-indolinona, intermediario de sintesis y una composicion farmaceutica que la comprende.
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
WO2010004339A1 (en) 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate
WO2010010454A2 (en) 2008-07-24 2010-01-28 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
WO2010011834A2 (en) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
WO2010023474A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel polymorphs of sunitinib and processes for their preparation
WO2010023473A2 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel crystalline form and processes for its preparation
EP2350056A1 (en) * 2008-10-10 2011-08-03 Medichem, S.A. Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
US8329740B2 (en) 2009-01-02 2012-12-11 Hetero Research Foundation Polymorphs of sunitinib malate
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
EP2477978A1 (en) 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Salts of sunitinib
EP2499133A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
EP2528913A1 (en) 2010-01-29 2012-12-05 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
CA2792039A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
US20160185760A1 (en) 2010-03-18 2016-06-30 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
WO2012145183A2 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2013140232A1 (en) 2012-03-23 2013-09-26 Laurus Labs Private Limited An improved process for the preparation of sunitinib and its acid addition salts thereof
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
EP3563865A3 (en) 2012-05-04 2019-12-04 Pfizer Inc Prostate-associated antigens and vaccine-based immunotherapy regimens
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
CA2838585A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta An ascorbic acid salt of sunitinib
DK3062815T3 (en) 2013-11-01 2019-03-11 Pfizer Vectors for expression of prostate-associated antigens
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
MX2021012515A (es) * 2019-04-18 2021-12-10 Meter Health Inc Metodos y composiciones para el tratamiento de arritmias respiratorias.
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651637B2 (en) 1990-10-15 1994-07-28 Pfizer Inc. Indole derivatives
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
SK279211B6 (sk) 1992-06-05 1998-08-05 Merck Sharp & Dohme Limited Sulfátová soľ substituovaného triazolu, spôsob jej
KR100296810B1 (ko) 1993-03-12 2001-10-24 로렌스 티. 마이젠헬더 결정성세프티오퍼유리산
US6288057B1 (en) * 1994-08-31 2001-09-11 Eli Lilly And Company Physical form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) * 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US6066647A (en) * 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
DK0920422T3 (da) * 1996-08-14 2003-03-17 Searle & Co Krystallinsk form af 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamid
CN1104378C (zh) * 1996-12-25 2003-04-02 日本化药株式会社 顺铂细粉及其制备方法
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
DE122010000013I1 (de) 1998-06-19 2010-07-08 Teijin Pharma Ltd Polymorphe modifikationen der 2-(3-cyano-4-isobutylphenyl)-4-methyl-5-thiazol-carbonsäure und verfahren zu ihrer herstellung
WO2000035908A1 (en) * 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
DK1233943T3 (da) * 1999-11-24 2011-08-15 Sugen Inc Ioniserbare indolinon derivater og anvendelse deraf som PTK ligander
EA005996B1 (ru) * 2000-02-15 2005-08-25 Сьюджен, Инк. Пирролзамещенный 2-индолинон, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
US6316672B1 (en) * 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
CN100364991C (zh) 2001-08-15 2008-01-30 法玛西雅厄普约翰美国公司 2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物
WO2009104021A2 (en) 2008-02-21 2009-08-27 Generics [Uk] Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Also Published As

Publication number Publication date
AR036261A1 (es) 2004-08-25
AP2004002976A0 (en) 2004-03-31
MXPA04001452A (es) 2004-05-20
ES2623094T3 (es) 2017-07-10
US20070191458A1 (en) 2007-08-16
EP2332934B1 (en) 2017-03-01
SI1419151T1 (sl) 2014-04-30
NO20041054L (no) 2004-03-12
MA27058A1 (fr) 2004-12-20
CA2455050C (en) 2007-02-20
JP4159988B2 (ja) 2008-10-01
JP2005503386A (ja) 2005-02-03
US7435832B2 (en) 2008-10-14
HRP20040112B1 (en) 2012-03-31
CA2455050A1 (en) 2003-02-27
CN1789264A (zh) 2006-06-21
CU20040029A7 (es) 2008-03-14
EA006445B1 (ru) 2005-12-29
BR0211612A (pt) 2004-08-24
PL216524B1 (pl) 2014-04-30
GEP20063777B (en) 2006-03-27
EP3168218B1 (en) 2018-11-14
ZA200400706B (en) 2005-05-25
EA200400183A1 (ru) 2004-08-26
IS7147A (is) 2004-02-10
DK1419151T3 (da) 2014-03-31
CN1543462A (zh) 2004-11-03
KR100639281B1 (ko) 2006-10-31
IL160097A0 (en) 2004-06-20
DK3168218T3 (en) 2019-01-14
PT1419151E (pt) 2014-03-27
HK1088008A1 (en) 2006-10-27
BG108553A (bg) 2005-04-30
EA006445B9 (ru) 2017-02-28
EP1419151A1 (en) 2004-05-19
ME00414B (me) 2011-10-10
ECSP044975A (es) 2004-03-23
PT3168218T (pt) 2019-01-11
TWI269796B (en) 2007-01-01
CN100439360C (zh) 2008-12-03
EP3168218A1 (en) 2017-05-17
OA12650A (en) 2006-06-19
TNSN04028A1 (fr) 2006-06-01
NZ531232A (en) 2004-11-26
HRP20040112A2 (en) 2004-06-30
ES2453164T3 (es) 2014-04-04
ES2705063T3 (es) 2019-03-21
TR201900509T4 (tr) 2019-02-21
NO326508B1 (no) 2008-12-15
CY1121552T1 (el) 2020-05-29
AP1660A (en) 2006-09-09
EP1419151B1 (en) 2014-02-26
EP2332934A1 (en) 2011-06-15
RS53251B (sr) 2014-08-29
WO2003016305A1 (en) 2003-02-27
HK1066542A1 (en) 2005-03-24
CZ2004196A3 (cs) 2005-01-12
PL368317A1 (en) 2005-03-21
SI3168218T1 (sl) 2019-05-31
CO5550431A2 (es) 2005-08-31
UA76483C2 (en) 2006-08-15
CN100364991C (zh) 2008-01-30
HU229206B1 (en) 2013-09-30
CU23713B7 (es) 2011-10-05
KR20040030074A (ko) 2004-04-08
MY139383A (en) 2009-09-30
RS10304A (en) 2007-02-05
US20030069298A1 (en) 2003-04-10
HUP0700036A2 (en) 2008-10-28
AU2002324684B2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
SK902004A3 (sk) Kryštály obsahujúce soľ N-[2-(dietylamino)etyl]-5-[(5-fluór-2- oxo-3H-indol-3-ylidén)metyl]-2,4,dimetyl-1H-pyrrol-3-karboxamidu s kyselinou jablčnou, spôsob ich výroby a kompozície na ich báze
AU2002324684A1 (en) Crystals including a malic acid salt of N-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3H-indole-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
RU2434851C1 (ru) Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
TW200838512A (en) Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof
KR100820511B1 (ko) 결정성 피라졸 유도체
CN113966332A (zh) Cdk9抑制剂的多晶型物及其制法和用途
CN111566101B (zh) Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用
WO2012122921A1 (zh) 一种酪氨酸激酶抑制剂的盐形式
WO2007146375A2 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
BRPI0616374B1 (pt) Forma i do sal de fosfato de um composto pirrol substituído 2-indolinona, composição farmacêutica, usos e método de preparação da forma i
EP3517529B1 (en) Salt of quinazoline derivative, preparation method therefor and application thereof
SK281782B6 (sk) Fumarátová soľ (r)-5-(metylaminosulfonyl-metyl)-3- (n-metylpyrolidin-2-ylmetyl)-1h-indolu, spôsob jej výroby, použitie a farmaceutický prostriedok
EA044623B1 (ru) Кристаллические формы соединения
US20030191140A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof

Legal Events

Date Code Title Description
FD9A Suspended procedure due to non-payment of fee